gatifloxacin has been researched along with Infections, Helicobacter in 8 studies
Gatifloxacin: A fluoroquinolone antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used as an ophthalmic solution for the treatment of BACTERIAL CONJUNCTIVITIS.
gatifloxacin : A monocarboxylic acid that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted on the nitrogen by a cyclopropyl group and at positions 6, 7, and 8 by fluoro, 3-methylpiperazin-1-yl, and methoxy groups, respectively. Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial topoisomerase type-II enzymes.
| Excerpt | Relevance | Reference |
|---|---|---|
| " No significant adverse effects were reported." | 2.72 | Efficacy and safety of rabeprazole, amoxicillin, and gatifloxacin after treatment failure of initial Helicobacter pylori eradication. ( Abdul-Baki, H; Aoun, E; Araj, GF; Chaar, HF; Kanj, SS; Sharara, AI, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (87.50) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Shao, Y | 1 |
| Lin, Y | 1 |
| Wang, B | 1 |
| Miao, M | 1 |
| Ye, G | 1 |
| Nishizawa, T | 2 |
| Suzuki, H | 2 |
| Nakagawa, I | 1 |
| Iwasaki, E | 2 |
| Masaoka, T | 2 |
| Hibi, T | 2 |
| Hori, K | 1 |
| Suguro, M | 1 |
| Koizuka, H | 1 |
| Sakagami, T | 1 |
| Tomita, T | 1 |
| Kosaka, T | 1 |
| Fukuda, Y | 1 |
| Sharara, AI | 2 |
| Chaar, HF | 2 |
| Racoubian, E | 1 |
| Moukhachen, O | 1 |
| Barada, KA | 1 |
| Mourad, FH | 1 |
| Araj, GF | 2 |
| Watanabe, K | 1 |
| Aoun, E | 1 |
| Abdul-Baki, H | 1 |
| Kanj, SS | 1 |
| Graham, DY | 1 |
| Abudayyeh, S | 1 |
| El-Zimaity, HM | 1 |
| Hoffman, J | 1 |
| Reddy, R | 1 |
| Opekun, AR | 1 |
| Umezawa, A | 1 |
| Muraoka, H | 1 |
| Kobayashi, I | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparison Between Ten Days Sequential Treatment (With Metronidazole or Tetracycline) and Ten Days Standard Triple Therapy of Helicobacter Pylori[NCT01573975] | Phase 4 | 345 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 trials available for gatifloxacin and Infections, Helicobacter
| Article | Year |
|---|---|
Gatifloxacin-based triple therapy as a third-line regimen for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Anti-Infective Agents; Clarithromycin; D | 2008 |
Efficacy of two rabeprazole/gatifloxacin-based triple therapies for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Efficacy and safety of rabeprazole, amoxicillin, and gatifloxacin after treatment failure of initial Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Bacterial Protei | 2006 |
5 other studies available for gatifloxacin and Infections, Helicobacter
| Article | Year |
|---|---|
Antibiotic resistance status of helicobacter pylori strains isolated from initial eradication patients in Ningbo, China, from 2017 to 2021.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Doxycycline; Drug Resistance, Bacterial; Fosfomy | 2022 |
Disappearance of rectal mucosa-associated lymphoid tissue lymphoma following antibiotic therapy.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Female; Fluoroquinolones; Gastritis; Gatifloxacin; H | 2004 |
[Evaluation of gatifloxacin-based triple therapy for refractory H. pylori].
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Evaluation; Drug Therapy, Combination | 2005 |
Sequential therapy using high-dose esomeprazole-amoxicillin followed by gatifloxacin for Helicobacter pylori infection.
Topics: Amoxicillin; Anti-Infective Agents; Clinical Protocols; Drug Administration Schedule; Drug Therapy, | 2006 |
Rapid detection of point mutations conferring resistance to fluoroquinolone in gyrA of Helicobacter pylori by allele-specific PCR.
Topics: Adult; Aged; Alleles; Anti-Infective Agents; DNA Gyrase; Drug Resistance, Bacterial; Female; Fluoroq | 2007 |